Progression of chronic obstructive pulmonary disease: Impact of inflammation, comorbidities and therapeutic intervention

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1235-1245

  Stockley, Robert A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Comorbidity; Disease progression; Inflammation; Inhaled corticosteroid; Long acting beta agonist

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; LONG ACTING DRUG; SALMETEROL; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; INFLAMMATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SMOKING CESSATION;

ANTI-INFLAMMATORY AGENTS; COMORBIDITY; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM;

EID: 67649224269     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902868971     Document Type: Review

References (118)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available at: www.goldcopd.com [Last accessed 18 February 2009]
2. World Health Organization (WHO). Chronic Obstructive Pulmonary Disease. 2007. Available at: www.who.int/respiratory/ copd/ [Last accessed 18 February 2009]
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504
4. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-532 (Pubitemid 44794666)
5. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. ProcAm Thoracic Soc 2006;3:619-623 (Pubitemid 44411630)
6. Miravitlles M, Murio C, Guerrero T et al, on behalf of the DAFNE Study Group. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003;123:784-791
7. Wouters EF. Economic analysis of the Confronting COPD Survey: an overview of results. Respir Med 2003;97(Suppl. C):S3-14 (Pubitemid 36266865)
8. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-708
9. Halpern MT, Polzin J, Higashi MK, et al. The workplace impact of acute exacerbations of chronic bronchitis (AECB): a literature review. COPD 2004;1:249-254
10. Seamark DA, Blake SD, Seamark CJ, et al. Living with severe chronic obstructive pulmonary disease (COPD): perceptions of patients and their carers. An interpretative phenomenological analysis. Palliat Med 2004;18:619-625
11. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805
12. Naberan K, De la Roza C, Lamban M, et al. Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in primary care. Arch Bronconeumol 2006;42:638-644 (Pubitemid 46132368)
13. Freeman D, Nordyke RJ, Isonaka S, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005;99:1311-1318 (Pubitemid 41245319)
14. Decramer M, Bartsch P, Pauwels R, et al. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis 2003;59:62-80
15. Altose MD. Approaches to slowing the progression of COPD. Curr Opin Pulm Med 2003;9:125-130 (Pubitemid 36184563)
16. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-682 (Pubitemid 40631293)
17. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360 (Pubitemid 36204553)
18. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004;59:574-580 (Pubitemid 38901515)
19. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-1257 (Pubitemid 44883863)
20. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006;7:70
21. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002;121:127S-30S (Pubitemid 34497329)
22. Wagena EJ, Arrindell WA, Wouters EF, et al. Are patients with COPD psychologically distressed? Eur Respir J 2005;26:242-248
23. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2005;2:26-33 (Pubitemid 40562960)
24. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-548 (Pubitemid 39658462)
25. Jeffery PK. Remodelling and inflammation of bronchia in asthma and chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2004;1:176-183
26. Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol 2004;50:Online Pub: OL627-37
27. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004;1:59-70
28. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721 (Pubitemid 39140629)
29. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653 (Pubitemid 38787999)
30. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151S-5S (Pubitemid 34497333)
31. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-762 (Pubitemid 36776358)
32. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of COPD are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-215
33. O'Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. Thorax 2006;61:448-454 (Pubitemid 43723331)
34. Dal Negro RW, Micheletto C, Tognella S, et al. A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations. COPD 2005;2:7-16 (Pubitemid 40776217)
35. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest 2007;131:1557-1566 (Pubitemid 46762366)
36. Stockley RA, Burnett D. Alpha,-antitrypsin and leukocyte elastase in infected and noninfected sputum. Am Rev Respir Dis 1979;120:1081-1086 (Pubitemid 10218496)
37. Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999;160:1968-1975 (Pubitemid 30004705)
38. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-280 (Pubitemid 30085952)
39. Stockley RA, Burnett D. Alpha 1-antichymotrypsin in infected and noninfected sputum. Am Rev Respir Dis 1980;122:81-88 (Pubitemid 10073545)
40. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-1645 (Pubitemid 30413357)
41. Gompertz S, O'Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-1119 (Pubitemid 32717466)
42. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-874 (Pubitemid 44564786)
43. Groenewegen KH, Postma DS, Hop WC, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008;133:350-357 (Pubitemid 351272391)
44. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:5s-13s (Pubitemid 37351732)
45. Aldonyte R, Eriksson S, Piitulainen E, et al. Analysis of systemic biomarkers in COPD patients. COPD 2004;1:155-164
46. Hersh CP, Demeo DL, Lazarus R, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:977-984
47. Hersh CP, Miller DT, Kwiatkowski DJ, et al. Genetic determinants of C-reactive protein in COPD. Eur Respir J 2006;28:1156-1162 (Pubitemid 44883850)
48. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD 2006;3:51-61
49. Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thoracic Soc 2006;3:276-280 (Pubitemid 43668194)
50. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004 (Pubitemid 41507533)
51. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-853 (Pubitemid 44570304)
52. Parr DG, White AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res 2006;7:136 (Pubitemid 44911885)
53. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:871-876
54. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19:189-199
55. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17-22 (Pubitemid 43106972)
56. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-120 (Pubitemid 30245950)
57. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-78 (Pubitemid 43069790)
58. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121 (Pubitemid 43726892)
59. Tumkaya M, Atis S, Ozge C, et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med 2007;101:729-737 (Pubitemid 46317242)
60. Snoeck-Stroband JB, Postma DS, Lapperre TS, et al. Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir Res 2006;7:140-147 (Pubitemid 44971092)
61. Van Helvoort HA, Heijdra YF, Thijs HM, et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006;38:1543-1552 (Pubitemid 44373772)
62. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23-28 (Pubitemid 43106973)
63. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-16 (Pubitemid 43106971)
64. Panina P, Mariani M, D'Ambrosio D. Chemokine receptors in chronic obstructive pulmonary disease (COPD). Curr Drug Targets 2006;7:669-674 (Pubitemid 43827262)
65. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-295
66. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-255 (Pubitemid 46203128)
67. Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respirology 2006;11:681-686 (Pubitemid 44581430)
68. Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004;114:370-378 (Pubitemid 39071609)
69. Chamberlain JS. Cachexia in cancer - zeroing in on myosin. N Engl J Med 2004;351:2124-2125 (Pubitemid 39482508)
70. Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712-1717 (Pubitemid 33124163)
71. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412 (Pubitemid 38534545)
72. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008;31:869-873
73. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-212
74. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007;4:522-525 (Pubitemid 47547846)
75. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809-814 (Pubitemid 37369571)
76. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789 (Pubitemid 46294610)
77. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD - Operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415 (Pubitemid 46698390)
78. Wood AM, Stockley RA. Unifying the genetics, co-morbidities and management of COPD. Ther Adv Respir Dis 2008;2:113-117 (Pubitemid 351818736)
79. Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-333 (Pubitemid 44266997)
80. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factoralpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-1455 (Pubitemid 24356667)
81. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28 (Pubitemid 40075677)
82. Albert MA, Danielson E, Rafai N, et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70 (Pubitemid 32606333)
83. Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Drugs Today (Barc) 2004;40:975-990 (Pubitemid 40128717)
84. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-283 (Pubitemid 46237383)
85. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-1505 (Pubitemid 24986688)
86. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239 (Pubitemid 40216240)
87. Celli BR, MacNee W, ATS/ERS committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
88. Okuyemi KS, Nollen NL, Ahluwalia JS. Interventions to facilitate smoking cessation. Am Fam Physician 2006;74:262-271 (Pubitemid 44099185)
89. Willemse BW, ten Hacken NH, Rutgers B, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26:835-845
90. Lapperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006;61:115-121 (Pubitemid 43235427)
91. Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007;30:467-471 (Pubitemid 351182069)
92. Willemse BW, ten Hacken NH, Rutgers B, et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J 2004;24:391-396
93. Garrod R, Ansley P, Canavan J, et al. Exercise and the inflammatory response in chronic obstructive pulmonary disease (COPD) - does training confer anti-inflammatory properties in COPD? Med Hypotheses 2007;68:291-298
94. Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001104
95. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312 (Pubitemid 37430563)
96. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006;61:854-862 (Pubitemid 44570305)
97. 1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007;131:682-689
98. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65 (Pubitemid 34775161)
99. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-997 (Pubitemid 41705466)
100. COMBIVENT Inhalation Aerosol Study GroupIn chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411-1419
101. Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998;65:354-362 (Pubitemid 28491270)
102. Baloira Villar A, Vilarino Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005;41:130-134 (Pubitemid 40469297)
103. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555 (Pubitemid 351650535)
104. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD003794 (Pubitemid 351805196)
105. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus longacting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD006829 (Pubitemid 351805194)
106. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD006826 (Pubitemid 351805193)
107. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456 (Pubitemid 36173708)
108. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919 (Pubitemid 37540641)
109. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81 (Pubitemid 36150304)
110. Celli B, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-338
111. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-1771
112. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743
113. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007;62:938-943 (Pubitemid 350084490)
114. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765 (Pubitemid 39298991)
115. Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002;110:S261-8 (Pubitemid 35471714)
116. Sin DD, Man SF. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 2006;533:28-35 (Pubitemid 43340002)
117. van der Vaart H, Koëter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-469 (Pubitemid 41121991)
118. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-934 (Pubitemid 46684703)